OCUGEN, INC. Form 8-K (April 21, 2021)

Summary

Current report on Form 8-K of Ocugen, Inc., dated April 21, 2021, filed under Items 8.01 and 9.01. It states that on April 21, 2021 the company issued a press release announcing that its co-development partner, Bharat Biotech International Limited, announced the results of the second interim analysis of its Phase 3 clinical trial of COVAXIN, a whole-virion inactivated COVID-19 vaccine candidate. The press release is Exhibit 99.1. The signature block shows /s/ Shankar Musunuri, Chief Executive Officer and Chairman, dated April 22, 2021.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section
13 OR 15 (d)

of the Securities
Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): April 21, 2021

OCUGEN, INC.

(Exact Name of Registrant as Specified in
its Charter)

Delaware | 001-36751 | 04-3522315
(State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification Number)

263 Great Valley Parkway

Malvern , Pennsylvania 19355

( 484 ) 328-4701

(Addresses, including zip code, and telephone
numbers, including area code, of principal executive offices)

N/A

(Former Name or Former Address, if Changed
Since Last Report)

Check the appropriate box below if the Form 8–K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ | Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ | Soliciting
material pursuant to Rule 14a–12 under the Exchange Act (17 CFR 240.14a–12)
¨ | Pre–commencement
communications pursuant to Rule 14d–2(b) under the Exchange Act (17 CFR 240.14d–2(b))
¨ | Pre–commencement
communications pursuant to Rule 13e–4(c) under the Exchange Act (17 CFR 240.13e–4(c))

Securities registered pursuant to Section
12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common Stock, $0.01 par value per share | OCGN | The Nasdaq Stock Market LLC (The Nasdaq Capital Market)

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging
growth company ¨

If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ¨

Item 8.01 Other Events

On April 21, 2021, Ocugen, Inc. issued
a press release announcing that its co-development partner, Bharat Biotech International Limited, announced the results of the second
interim analysis of its Phase 3 clinical trial of COVAXIN, a whole-virion inactivated COVID-19 vaccine candidate. A copy of this press
release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

The following exhibit is being filed herewith:

(d) Exhibits

Exhibit No. | Document
99.1 | Press Release of Ocugen, Inc. dated April 21, 2021.
104 | Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934,
as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: April 22, 2021

OCUGEN, INC.
By: | /s/ Shankar Musunuri
Name: Shankar Musunuri
Title: Chief Executive Officer and Chairman

File and source

File

SEC_OCGN_8-K_filed2021-04-22_0001104659-21-053355.htm

Size

26,657 bytes

SHA-256

eb82570cc782a5b6c4547b813aa542517e4a6eedcf86395b25606bb1e41b1b7f

Our copy

SEC_OCGN_8-K_filed2021-04-22_0001104659-21-053355.htm

Original

www.sec.gov